{"id":"ipratropium-bromide-hfa-inhalation-aerosol","safety":{"commonSideEffects":[{"rate":"10%","effect":"Cough"},{"rate":"5%","effect":"Dysphonia"},{"rate":"5%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2134724","moleculeType":"Small molecule","molecularWeight":"430.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ipratropium bromide is a non-selective muscarinic receptor antagonist that inhibits the action of acetylcholine at muscarinic receptors in the lungs, thereby reducing bronchospasm and mucus secretion.","oneSentence":"Anticholinergic agent that inhibits muscarinic acetylcholine receptors","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:56:20.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT02182674","phase":"PHASE2","title":"A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":66},{"nctId":"NCT01350128","phase":"PHASE2","title":"PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2011-05-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":103},{"nctId":"NCT02260011","phase":"PHASE2","title":"Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":41},{"nctId":"NCT02236169","phase":"PHASE2","title":"Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT00605410","phase":"PHASE4","title":"Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2008-01","conditions":"Asthma","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atrovent"],"phase":"phase_2","status":"active","brandName":"Ipratropium Bromide HFA Inhalation Aerosol","genericName":"Ipratropium Bromide HFA Inhalation Aerosol","companyName":"Pearl Therapeutics, Inc.","companyId":"pearl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anticholinergic agent that inhibits muscarinic acetylcholine receptors Used for Chronic obstructive pulmonary disease (COPD), Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}